AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Therapeutics for Triple Negative Breast Cancer

Summary

Researchers at Purdue University have developed a new technology that could change how breast cancer is treated. The researchers have developed new drug candidates that are potent at lower concentrations than chemotherapy. The technology employs molecules that are selectively taken up by cancer cells and activated by light. In vitro, this therapeutic drug is photoactive at the nanomolar range with an appropriate light dose adjustment and has no observable toxicity when not exposed to light. This targeted therapy promises to reduce the dosage of drug needed to treat TNBC and effectively reduce side effects.

Technology Benefits

Reduced adverse effectsTargeted therapy Potent at low concentrations

Technology Application

Breast cancer Cancer therapeutics

Detailed Technology Description

Meden F. Isaac-LamPurdue Northwest Biological Sciences

Countries

United States

Application No.

None

Country/Region

USA

For more information, please click Here